Frankfurt, 25. April 2012
Deutsche Bank exits Actavis loan
Diese Information ist nur in englischer Sprache verfügbar.
Deutsche Bank (XETRA: DBKGn.DE / NYSE: DB) announced today that it will exit its exposure to Actavis, the generic pharmaceuticals company, upon completion of Watson Pharmaceuticals' acquisition of Actavis.
This triggered an impairment charge of EUR 257 million in the first quarter. The transaction is expected to close in the fourth quarter of 2012, at which time there will be Core Tier 1 capital accretion of approximately EUR 290 million.
Overall, it will have a net positive impact on the Group's Core Tier 1 capital ratio of approximately 6 basis points in 2012.
This further demonstrates the Group's commitment to reducing non-core legacy positions and associated risk in a capital efficient manner.
This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations and the assumptions underlying them. These statements are based on plans, estimates and projections as they are currently available to the management of Deutsche Bank. Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events.
By their very nature, forward-looking statements involve risks and uncertainties. A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include the conditions in the financial markets in Germany, in Europe, in the United States and elsewhere from which we derive a substantial portion of our revenues and in which we hold a substantial portion of our assets, the development of asset prices and market volatility, potential defaults of borrowers or trading counterparties, the implementation of our strategic initiatives, the reliability of our risk management policies, procedures and methods, and other risks referenced in our filings with the U.S. Securities and Exchange Commission. Such factors are described in detail in our SEC Form 20-F of 20 March 2012 under the heading “Risk Factors.” Copies of this document are readily available upon request or can be downloaded from www.deutsche-bank.com/ir.